Neurosciences

CellCarta has a unique expertise in the proteomic analysis of biomarkers relevant to neurological disorders.  As a member of the Biomarkers Consortium led by The Foundation for the National Institutes of Health (FNIH), CellCarta established robust mass spectrometry workflows for the analysis of cerebrospinal fluid (CSF) and developed a multiple reaction monitoring (MRM) panel used for the measurement of  CSF protein biomarkers.

CellCarta worked with biopharmaceutical partners along with non-for-profit organizations such as the Michael J. Fox Foundation, leveraging its know-how for the study of important neurological disorders such as Alzheimer’s disease, Parkinson’s disease, Schizophrenia, and Huntington’s disease.

In addition to our biomarker development work, we can leverage Olink PEA technology, MSD, and the MRM platform to provide relative and absolute quantification of biomarkers in several clinical matrices, including cerebrospinal fluid (CSF). Olink is a high-multiplex technology that allows for the quantification of protein biomarkers using minimal sample volume with disease specific panels such as the Neurology and Neuro Exploratory panels.

We also developed targeted MRM pharmacokinetics (PK) assays for the absolute quantification of biotherapeutics in various biological matrices such as brain tissue, CSF, and plasma.

Here are some examples of work we did in the field of neurosciences:

Finding Useful Biomarkers for Parkinson’s Disease.

Development and Evaluation of a Multiplexed Mass Spectrometry-Based Assay for Measuring Candidate Peptide Biomarkers in Alzheimer’s Disease Neuroimaging Initiative (ADNI) CSF.